
GLOBUS MEDICAL INC - A
GMEDNYSETrading Snapshot
- Day Range
- $83.80 โ $86.75
- 52-Week Range
- $54.15 โ $101.40
- Volume
- $2.78B
- Avg Volume
- $3.69B
- Shares Outstanding
- 135.7M
- Next Earnings
- Oct 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.94B
- Last Q Revenue
- $790M
- P/E Ratio
- 20.8
- P/S Ratio
- 3.5x
- EPS (TTM)
- $3.91
- Dividend Yield
- โ
Why Investors Own GMED
- โHigh-growth profile โ revenue up +59.3% YoY with expanding US Equity exposure.
- โHealthy economics โ 61% gross margin and 28% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About GLOBUS MEDICAL INC - A
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Globus Medical Q2 Earnings Call Highlights
Globus Medical (NYSE:GMED) reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted

Globus Medical (NYSE:GMED): A Compelling Affordable Growth Opportunity
GMED earns top scores in growth, value, profitability & financial health, making it a standout pick in the Affordable Growth screen.

GMED Q2 Earnings Call Highlights Margin Gains and Revenue Caution
Globus Medical raises 2026 EPS guidance after Q2 margin gains and spine growth while holding sales guidance steady amid Nevro and Enabling Technologies risks.
Wells Fargo Maintains Overweight on Globus Medical, Lowers Price Target to $99
Wells Fargo analyst Larry Biegelsen maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $103 to $99.

Globus Medical Inc (GMED) (Q2 2026) Earnings Call Highlights: Record EPS and Margin Expansion ...
Globus Medical Inc (GMED) delivers record Q2 EPS with 56% growth, while navigating Nevro stabilization and enabling tech transition.
Globus Medical (NYSE:GMED) Shares Rise on Q2 Earnings Beat and Raised Profit Guidance
Globus Medical beats Q2 earnings, raises FY profit guidance; revenue slightly misses but shares rise ~3% after hours.